Defending Against Claims Alleging Allergic Hypersensitivity

Live · 2 CLE credits · November 18, 2026, 2:30 PM ET

An allergic reaction is not a defect. Learn to attack causation with dose, route, and threshold-dose science, deploy Rule 12 and preemption motions, challenge plaintiffs' experts under Rule 702, and carry a science-driven defense theme through trial.

An allergic reaction is not a product defect — and the whole case turns on whether you can prove it

Allergic hypersensitivity claims — contact, respiratory, food, and drug — are being reshaped by recent law. The 2023 amendments to Rule 702 sharpened judicial gatekeeping, and the Supreme Court's 2026 decision in Monsanto v. Durnell extended labeling preemption from medical devices to EPA-registered products.

The stakes are already concrete. Plead without product-specific facts, and Twiqbal ends the case at Rule 12. Miss the sensitizer-versus-irritant distinction, and the causation record unravels. Skip a threshold-dose assessment, and In re Zantac says the claim should not survive. Overlook Riegel and Durnell, and a preemption defense goes unused.

Attendees leave with phase-by-phase practice pointers from intake to verdict: analyzing the complaint, Rule 12 and preemption motions, discovery aimed at dose and route, deposing and crossing plaintiffs' experts, Rule 702 and summary judgment briefing, and science-grounded defense themes built for a jury.

Key topics

Agenda

Faculty

State accreditation